Anticancer mechanism and application of curcumin analog EF24

Abstract

Ling Xiaofei, Xu Ke, Shao Hua, Wang Cuijuan. Anticancer mechanism and application of curcumin analog EF24[J]. Journal of International Oncology, 2018, 45(3): 172-175.

［1］ Wu JZ, Wu SB, Shi LY, et al. Design, synthesis, and evaluation of asymmetric EF24 analogues as potential anticancer agents for lung cancer［J］. Eur J Med Chem, 2017, 125: 1321-1331. DOI: 10.1016/j.ejmech.2016.10.027. ［2］韩金荣, 张林西. 姜黄素抗肿瘤作用机制［J］. 国际肿瘤学杂志, 2013, 40(11): 823-826. DOI: 10.3760/cma.j.issn.1673-422X.2013.11.007. ［3］ Bisht S, Schlesinger M, Rupp A, et al. A liposomal formulation of the synthetic curcumin analog EF24 (LipoEF24) inhibits pancreatic cancer progression: towards future combination therapies［J］. J Nanobiotechnology, 2016, 14(1): 57. DOI: 10.1186/s12951-016-0209-6. ［4］ He G, Feng C, Vinothkumar R, et al. Curcumin analog EF24 induces apoptosis via ROSdependent mitochondrial dysfunction in human colorectal cancer cells［J］. Cancer Chemother Pharmacol, 2016, 78(6): 1151-1161. DOI: 10.1007/s00280-016-3172-x. ［5］ Yang CH, Yue J, Sims M, et al. The curcumin analog EF24 targets NFκB and miRNA-21, and has potent anticancer activity in vitro and in vivo［J］. PLoS One, 2013, 8(8): e71130. DOI: 10.1371/journal.pone.0071130. ［6］ Kasinski AL, Du Y, Thomas SL, et al. Inhibition of IkappaB kinasenuclear factorkappaB signaling pathway by 3,5bis(2flurobenzylidene)piperidin4one (EF24), a novel monoketone analog of curcumin［J］. Mol Pharmacol, 2008, 74(3): 654661. DOI: 10.1124/mol.108.046201. ［7］ Yin DL, Liang YJ, Zheng TS, et al. EF24 inhibits tumor growth and metastasis via suppressing NFkappaB dependent pathways in human cholangiocarcinoma［J］. Sci Rep, 2016, 6: 32167. DOI: 10.1038/srep32167. ［8］ Raj L, Ide T, Gurkar AU, et al. Selective killing of cancer cells by a small molecule targeting the stress response to ROS［J］. Nature, 2011, 475(7355): 231-234. DOI: 10.1038/nature10167. ［9］ Peng Z, Xia Y, Chen W, et al. EF24 induces ROSmediated apoptosis via targeting thioredoxin reductase 1 in gastric cancer cells［J］. Oncotarget, 2016, 7(14): 18050-18064. ［10］ Thomas SL, Zhong D, Zhou W, et al. EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF1［J］. Cell Cycle, 2008, 7(15): 2409-2417. DOI: 10.4161/cc.6410. ［11］ Fragkos M, Ganier O, Coulombe P, et al. DNA replication origin activation in space and time［J］. Nat Rev Mol Cell Biol, 2015, 16(6): 360-374. DOI: 10.1038/nrm4002. ［12］ Liu HT, Liang YJ, Wang LL, et al. In vivo and in vitro suppression of hepatocellular carcinoma by EF24, a curcumin analog［J］. PLoS One, 2012, 7(10): e48075. DOI: 10.1371/journal.pone.0048075. ［13］ Meek DW. Regulation of the p53 response and its relationship to cancer［J］. Biochem J, 2015, 469(3): 325-346. DOI: 10.1042/BJ20150517. ［14］ Subramaniam D, May R, Sureban SM, et al. Diphenyl difluoroketone: a curcumin derivative with potent in vivo anticancer activity［J］. Cancer Res, 2008, 68(6): 1962-1969. DOI: 10.1158/00085472.CAN-07-6011. ［15］ Dvorak HF. Tumors: wounds that do not healredux［J］. Cancer Immunol Res, 2015, 3(1): 1-11. DOI: 10.1158/23266066.CIR-14-0209. ［16］李纯苓, 王朝霞, 王恒孝. HIF1α、PDGF与VEGF、VEGFR在乳腺癌发病中的表达及意义［J］. 国际肿瘤学杂志, 2014, 41(11): 858-865. DOI: 10.3760/cma.j.issn.1673-422X.2014.11.018. ［17］ Liu W, Kovacevic Z, Peng Z, et al. The molecular effect of metastasis suppressors on Src signaling and tumorigenesis: new therapeutic targets［J］. Oncotarget, 2015, 6(34): 35522-35541. DOI: 10.18632/oncotarget.5849. ［18］ Zhao R, Tin L, Zhang Y, et al. EF24 suppresses invasion and migration of hepatocellular carcinoma cells in vitro via inhibiting the phosphorylation of Src［J］. Biomed Res Int, 2016, 2016: 8569684. DOI: 10.1155/2016/8569684. ［19］曹纯, 马晓洁, 谭榜宪. 缺氧诱导因子-1α与上皮间质转化［J］. 国际肿瘤学杂志, 2014, 41(6): 415-418. DOI: 10.3760/cma.j.issn.1673-422X.2014.06.005. ［20］ Zhang P, Bai H, Liu G, et al. MicroRNA33b, upregulated by EF24, a curcumin analog, suppresses the epithelialtomesenchymal transition (EMT) and migratory potential of melanoma cells by targeting HMGA2［J］. Toxicol Lett, 2015, 234(3): 151161. DOI: 10.1016/j.toxlet.2015.02.018. ［21］ Zhang D, Wang Y, Dong L, et al. Therapeutic role of EF24 targeting glucose transporter 1mediated metabolism and metastasis in ovarian cancer cells［J］. Cancer Sci, 2013, 104(12): 1690-1696. DOI: 10.1111/cas.12293. ［22］ Liang Y, Yin D, Hou L, et al. Diphenyl difluoroketone: a potent chemotherapy candidate for human hepatocellular carcinoma［J］. PLoS One, 2011, 6(8): e23908. DOI: 10.1371/journal.pone.0023908. ［23］ Chen W, Zou P, Zhao Z, et al. Synergistic antitumor activity of rapamycin and EF24 via increasing ROS for the treatment of gastric cancer［J］. Redox Biol, 2016, 10: 78-89. DOI: 10.1016/j.redox.2016.09.006. ［24］ Onen HI, Yilmaz A, Alp E, et al. EF24 and RAD001 potentiates the anticancer effect of platinumbased agents in human malignant pleural mesothelioma (MSTO211H) cells and protects nonmalignant mesothelial (MET5A) cells［J］. Hum Exp Toxicol, 2015, 34(2): 117-126. DOI: 10.1177/0960327114542965. ［25］ Liang Y, Zheng T, Song R, et al. Hypoxiamediated sorafenib resistance can be overcome by EF24 through Von HippelLindau tumor suppressordependent HIF-1α inhibition in hepatocellular carcinoma［J］. Hepatology, 2013, 57(5): 1847-1857. DOI: 10.1002/hep.26224. ［26］ Aravindan S, Natarajan M, Awasthi V, et al. Novel synthetic monoketone transmute radiationtriggered NFκBdependent TNFα crosssignaling feedback maintained NFκB and favors neuroblastoma regression［J］. PLoS One, 2013, 8(8): e72464. DOI: 10.1371/journal.pone.0072464.

[1]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[2]	Wang Liwei, Liang Hongsheng, Du Songlin, Chen Zhihao, Wang Qing, Gao Aili.Research progress of avermectins in anti-tumor[J]. Journal of International Oncology, 2022, 49(6): 353-356.
[3]	Wang Shuang, Tang Yunyun, Yue Qi.New progress in antitumor research of non-psychoactive cannabidiol[J]. Journal of International Oncology, 2020, 47(10): 619-623.
[4]	Yi Lin, Qiu Shi.Anti-tumor effect and mechanisms of shikonin on gliomas[J]. Journal of International Oncology, 2019, 46(8): 489-491.
[5]	Liang Jing1,3, Han Sha2, Yao Jing3, Kong Qingsheng2.Effect of histone deacetylase and its inhibitor on tumor[J]. Journal of International Oncology, 2019, 46(4): 235-238.
[6]	Xiong Bobo, Zhang Jinsong, Li Ning, Wang Haifeng, Zuo Yigang, Wang Jiansong.Molecular targeted therapy for advanced kidney cancer[J]. Journal of International Oncology, 2019, 46(12): 705-710.
[7]	Wang Gang, Wang Huangzhen, Xue Ting.Effect of oxaliplatin induced autophagy on drug resistance of SGC7901 gastric cancer cells[J]. Journal of International Oncology, 2018, 45(8): 513-518.
[8]	Chen Gang, Zhuang Fangcheng.High mobility group box 1 and its role in cervical cancer[J]. Journal of International Oncology, 2017, 44(3): 235-238.
[9]	Liu Lan, Zhang Zhimin, Peng Wenmiao, Fu Hongxing, Rao Zhiguo.Reversal of Pglycoproteinmediated multidrug resistance mechanism by curcumin[J]. Journal of International Oncology, 2017, 44(10): 758-761.
[10]	Dong Yi, Wei Yuehua, Hu Weiguo, Song Qibin.Therapy for non-small cell lung cancer patients with solitary bone metastases[J]. Journal of International Oncology, 2017, 44(1): 60-62.
[11]	Cai Xiaojun, Han Lijuan, Wei Ping.Curcumin downregulation of MGMT expression to enhance the chemosensitivity of temozolomide on maligant glioblastoma[J]. Journal of International Oncology, 2016, 43(8): 565-569.
[12]	DU Ji-Hui, ZHANG Hou-De, WEI Jing, WANG Lei, SUN Ting-Ji.Correlation of peroxisome pathway reactive oxygen species oxidative stress gene and its correlation with the antitumor sensitivity of artesunate against pancreatic cancer[J]. Journal of International Oncology, 2016, 43(7): 503-507.
[13]	Tian Ruonan,Sun Jianjing, Zhang Linxi.Mechanism of curcumin resisting esophageal cancer[J]. Journal of International Oncology, 2016, 43(5): 379-381.
[14]	LIU Dong-Ju, ZHAO Qiu-Sheng, YAO Yu.Effects of curcumin combined with cisplatin on growth and lymphatic metastasis of cervical cancer xenografts in nude mice[J]. Journal of International Oncology, 2016, 43(4): 241-245.
[15]	ZHANG Wen-Dian, XU Zu-Min, YU Zhong-Hua.Antitumor mechanism of gambogic acid[J]. Journal of International Oncology, 2016, 43(4): 293-295.

Anticancer mechanism and application of curcumin analog EF24

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments